Grifols (GRFS) Treasury Shares (2009 - 2025)
Grifols' (GRFS) quarterly Treasury Shares came in at $152.5 million in Q4 2025, up 5.7% YoY from $144.3 million in Q4 2024, and up 5.7% on a QoQ basis from $144.3 million in Q4 2024.
Grifols (GRFS) Treasury Shares (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Treasury Shares data on file, last reported at $152.5 million in Q4 2025.
- Quarterly Treasury Shares rose 5.7% year-over-year to $152.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $152.5 million (up 5.7% YoY) and the FY2025 annual result came in at $152.5 million, up 5.7% from the prior year.
- Treasury Shares climbed to $152.5 million in Q4 2025, from $144.3 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $5.8 million in Q4 2021 to a low of $3.4 million in Q4 2024.
- A 5-year average of $4.8 million and a median of $4.9 million in 2023 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2021 — Treasury Shares jumped 260.21% — and 2024, when it decreased 12.22%.
- Tracing GRFS's Treasury Shares over 5 years: stood at $187.8 million in 2021, then fell by 11.88% to $165.5 million in 2022, then retreated by 0.7% to $164.3 million in 2023, then dropped by 12.22% to $144.3 million in 2024, then rose by 5.7% to $152.5 million in 2025.
- The last three Treasury Shares figures came in at $152.5 million (Q4 2025), $144.3 million (Q4 2024), and $164.3 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 470.18 Bn | 463.61 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 376.85 Bn | 369.71 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.42 Bn | 252.52 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.16 Bn | 178.98 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.30 Bn | 147.60 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.43 Bn | 4.43 Bn | - | 152.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 152.49 Mn |
| Dec 31, 2025 | 152.49 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Dec 31, 2024 | 3.42 Mn |
| Dec 31, 2024 | 3.42 Mn |
| Dec 31, 2024 | 144.26 Mn |
| Dec 31, 2024 | 144.26 Mn |
| Dec 31, 2023 | 164.35 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Dec 31, 2023 | 164.35 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Dec 31, 2022 | 5.31 Mn |
| Dec 31, 2022 | 165.50 Mn |
| Dec 31, 2022 | 165.50 Mn |
| Dec 31, 2021 | 5.80 Mn |
| Dec 31, 2021 | 5.80 Mn |
| Dec 31, 2021 | 187.83 Mn |
| Dec 31, 2021 | 187.83 Mn |